

AMENDMENTS TO THE CLAIMS

1. (Cancelled)
2. (Cancelled)
3. (Currently Amended) The siNA siRNA molecule of claim 37, wherein said siNA siRNA molecule comprises one or more ribonucleotides.
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Currently Amended) The siNA siRNA molecule of claim 37, wherein the first strand includes a terminal cap moiety at the 5'-end, the 3'-end, or both the 5' and 3' ends of the first strand.

17. (Currently Amended) The siNA siRNA molecule of claim 16, wherein said terminal cap moiety is an inverted deoxy abasic moiety.
18. (Cancelled)
19. (Cancelled)
20. (Cancelled)
21. (Currently Amended) The siNA siRNA molecule of claim 37, wherein said siNA siRNA comprises one of more phosphorothioate linkages.
22. (Cancelled)
23. (Currently Amended) The siNA siRNA molecule of claim 37, wherein each of the two strands of said siNA siRNA molecule comprise 21 nucleotides.
24. (Currently Amended) The siNA siRNA molecule of claim 23, wherein about 19 nucleotides of each strand of the siNA siRNA molecule are base-paired to the complementary nucleotides of the other strand of the siNA siRNA molecule and wherein at least two 3' terminal nucleotides of each strand of the siNA siRNA molecule are not base-paired to the nucleotides of the other strand of the siNA siRNA molecule.
25. (Cancelled)
26. (Cancelled)
27. (Cancelled)
28. (Cancelled)
29. (Cancelled)
30. (Currently Amended) The siNA siRNA molecule of claim 37, wherein the 5'-end of said second strand includes a phosphate group.

31. (Cancelled)
32. (Cancelled)
33. (Currently Amended) A pharmaceutical composition comprising the siNA siRNA molecule of claim 37 in an acceptable carrier or diluent.
34. (Cancelled)
35. (Cancelled)
36. (Cancelled)
37. (Currently Amended) A chemically synthesized double stranded short interfering nucleic acid (siNA) RNA (siRNA) molecule consisting essentially of a first nucleic acid strand and a second nucleic acid strand, wherein
 - a. the first strand has complementarity to the second strand;
 - b. the second strand has 18-24 nucleotides complementary to a human synuclein-1 (SNCA) RNA comprising SEQ ID NO:311; and
 - c. one or more pyrimidine nucleotides present in the first strand or second strand of the siNA siRNA molecule has at least one sugar modification is a 2'-deoxy-2'-fluoro pyrimidine nucleotide.
38. (Cancelled)
39. (Cancelled)
40. (Cancelled)